Clinical Trial Update: Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I–II study evaluating tumor molecular pharmacodynamics and pharmacokinetics of palbociclib (PD-0332991) in patients with metastatic melanoma, including BR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Melanoma BRAF V600E/K Mutated, CDNKN2A Loss Defined | Phase 1, Phase 2 | Status: UNKNOWN